Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jan 2:8:2.
doi: 10.1186/1471-2334-8-2.

Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART

Affiliations

Low-level HIV-1 replication and the dynamics of the resting CD4+ T cell reservoir for HIV-1 in the setting of HAART

Ahmad R Sedaghat et al. BMC Infect Dis. .

Abstract

Background: In the setting of highly active antiretroviral therapy (HAART), plasma levels of human immunodeficiency type-1 (HIV-1) rapidly decay to below the limit of detection of standard clinical assays. However, reactivation of remaining latently infected memory CD4+ T cells is a source of continued virus production, forcing patients to remain on HAART despite clinically undetectable viral loads. Unfortunately, the latent reservoir decays slowly, with a half-life of up to 44 months, making it the major known obstacle to the eradication of HIV-1 infection. However, the mechanism underlying the long half-life of the latent reservoir is unknown. The most likely potential mechanisms are low-level viral replication and the intrinsic stability of latently infected cells.

Methods: Here we use a mathematical model of T cell dynamics in the setting of HIV-1 infection to probe the decay characteristics of the latent reservoir upon initiation of HAART. We compare the behavior of this model to patient derived data in order to gain insight into the role of low-level viral replication in the setting of HAART.

Results: By comparing the behavior of our model to patient derived data, we find that the viral dynamics observed in patients on HAART could be consistent with low-level viral replication but that this replication would not significantly affect the decay rate of the latent reservoir. Rather than low-level replication, the intrinsic stability of latently infected cells and the rate at which they are reactivated primarily determine the observed reservoir decay rate according to the predictions of our model.

Conclusion: The intrinsic stability of the latent reservoir has important implications for efforts to eradicate HIV-1 infection and suggests that intensified HAART would not accelerate the decay of the latent reservoir.

PubMed Disclaimer

Figures

Figure 1
Figure 1
General schematic of model reflecting uninfected cells (U), productively infected cells (P) and latently infected cells (L). λ represents target T cell production. β reflects virus infectivity. αR is the rate of reversion for productively infected cells to latency. αQ is the activation rate of latently infected cells. Uninfected, productively infected and latently infected cells each have intrinsic death rates represented by δU, δP and δL, respectively.
Figure 2
Figure 2
Dependence of the latent reservoir decay rate, Λ, on the degree of residual viral replication, r, plotted as Λ vs. 1 - r, for parameter values: λ = 2 × 109 cells/day, αR = αQ/100, δU = 0.02 day-1, δL = 0.0001 day-1, and L¯/U¯ = 1 × 10-4. We consider 3 different pairs of δP and αQ values. The predicted value of r*, color coded for each case, is marked at the top of the plot. The marker * indicates the similar r = βcrit/βuntreated value for every pair of δP and αQ.
Figure 3
Figure 3
Decay of (A) productively infected cells (total number of cells) for different degrees of viral infectivity under optimal suppression (βHAART <βcrit) of replication by HAART (r = 0 and 0.95 βcrit/βuntreated) for different values of δU (= 0.02 day-1 and 0.10 day-1). Decay of productively infected cells for different degrees of viral infectivity under sub-optimal suppression (βHAART > βcrit) by HAART for (B) δU = 0.02 day-1 where βcrit/βuntreated ≈ 0.769 and (C) δU = 0.20 day-1 where βcrit/βuntreated ≈ 0.970 (D) Clinically observed decay of viral load after initiation of HAART for 2 HIV+ patients with no history of drug resistance: pt. 135 (blue) and pt. 140 (red). Pt. 135's viral load has remained undetectable for an additional 5 years with only 1 blip and pt. 140's viral load has remained undetectable for 1 additional year (data not shown). Open faced markers represent undetectable viral load measurements at the limit of detection for the assay used. (E) Decay of latently infected cells (total number of cells) for different degrees of viral infectivity, where βcrit/βuntreated ≈ 0.769. All simulations were performed with model parameter values listed in Table 1 unless otherwise specified.
Figure 4
Figure 4
Decay of the latent reservoir as a function of time for (A) different degrees of HAART suppression of viral infectivity, r = 0 (black), 0.769 (βcrit/βuntreated) (blue), 0.80 (green), 0.90 (red); and (B) different activation rates, αQ = 0.0005 day-1 (black), 0.001 day-1 (blue), 0.0025 day-1 (green) and 0.005 day-1 (red). Parameter values, unless otherwise specified, are: λ = 2 × 109 cells/day, β = 0, αQ = 0.0005 day-1, αR = αQ/100, δU = 0.02 day-1, δP = 0.50 day-1, δL = 0.0001 day-1 and L¯/U¯ = 1 × 10-4.

Similar articles

Cited by

References

    1. Chun TW, Finzi D, Margolick J, Chadwick K, Schwartz D, Siliciano RF. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transition to stable latency. Nat Med. 1995;1:1284–1290. doi: 10.1038/nm1295-1284. - DOI - PubMed
    1. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, Fauci AS. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA. 1997;94:13193–13197. doi: 10.1073/pnas.94.24.13193. - DOI - PMC - PubMed
    1. Chun TW, Carruth L, Finzi D, Shen X, DiGiuseppe JA, Taylor H, Hermankova M, Chadwick K, Margolick J, Quinn TC, Kuo YH, Brookmeyer R, Zeiger MA, Barditch-Crovo P, Siliciano RF. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997;387:183–188. doi: 10.1038/387183a0. - DOI - PubMed
    1. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278:1295–1300. doi: 10.1126/science.278.5341.1295. - DOI - PubMed
    1. Hermankova M, Siliciano JD, Zhou Y, Monie D, Chadwick K, Margolick JB, Quinn TC, Siliciano RF. Analysis of human immunodeficiency virus type 1 gene expression in latently infected resting CD4+ T lymphocytes in vivo. J Virol. 2003;77:7383–7392. doi: 10.1128/JVI.77.13.7383-7392.2003. - DOI - PMC - PubMed

Publication types